Doctor One
About
What is Doctor One's revenue?
StartupHub estimates Doctor One's annual revenue at $1.3M (range $406K to $4.8M, 31% confidence), based on comparable companies in the sector.
What is Doctor One's valuation?
StartupHub estimates Doctor One's effective valuation at $25.3M (range $17.1M to $40.9M, 12% confidence), based on comparable companies in the sector.
How much funding has Doctor One raised?
Doctor One has raised a total of $7M in funding. The most recent round on record is Seed.
Where is Doctor One headquartered?
Doctor One is headquartered in Tel Aviv, Israel.
When was Doctor One founded?
Doctor One was founded in 2022.
What industry does Doctor One operate in?
Doctor One operates in HealthTech, Telemedicine, AI-Driven Health, Personalized Health, Wellness, Conversational AI.
What is Doctor One's current status?
Doctor One's current operating status is: Inactive.
AI-powered platform for healthcare providers to manage patient WhatsApp messages efficiently.
AI-powered platform for personalized weight management and health coaching.
Recordatorios por WhatsApp para el paciente y tranquilidad para quien lo acompaña. Gratis, sin apps que descargar.
Clinical Trial Discovery by ENSCORE.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
SYLARIS™ offers premium wearable wellness patches and clinical-grade skincare designed for effortless, intentional, and beautifully designed self-care rituals.
A research organization quantifying impact-focused investments using advanced AI methods to create rigorous, comparable metrics.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 7 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.